GlassScriptPhysician profile
Harvey A Snyder
NPI 1003869488
$6,277.03
in general payments reported to CMS, 2019-2025
34 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $471 · 2021: $933 · 2022: $1,012 · 2023: $623 · 2024: $1,295 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,331.45 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $914.79 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $649.39 | 2021-2025 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $345.14 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $340.31 | 2019-2024 | Xarelto |
| Amgen INC. | $329.49 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $326.80 | 2019-2025 | |
| Abbott Laboratories | $282.86 | 2022-2025 | Absolute Pro, Perclose Prostyle, Cardiomems |
| Amarin Pharma, INC. | $274.34 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $263.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $174.45 | 2021-2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $141.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.60 | 2021-2025 | |
| Atricure, INC. | $87.23 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $81.38 | 2019-2025 | Evkeeza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $71.69 | 2021-2025 | Wegovy |
| Esperion Therapeutics, INC. | $68.69 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.27 | 2021-2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $59.56 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $53.91 | 2019-2021 | |
| Boston Scientific Corporation | $53.10 | 2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $38.62 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $30.93 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $30.06 | 2023-2024 | Assure Wcd |
| Tactile Systems Technology INC | $23.73 | 2024 | Flexitouch Plus, Entre Plus |
| Genzyme Corporation | $20.02 | 2024 | |
| Glaxosmithkline, LLC. | $18.40 | 2025 | Shingrix, Arexvy |
| Regeneron Pharmaceuticals, INC. | $16.80 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.03 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $15.55 | 2023 | Opsumit |
| Heartflow, INC. | $14.10 | 2024 | |
| Scpharmaceuticals INC. | $14.09 | 2023 | |
| Inspire Medical Systems, INC. | $13.21 | 2024 | Inspire |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.